CohBar to Present at Upcoming Investor Conferences
September 02 2021 - 4:05PM
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company
developing mitochondria based therapeutics to treat chronic
diseases and extend healthy lifespan, announced today that its
Chief Executive Officer, Dr. Joseph Sarret, will present a company
overview at the following investor conferences in September.
H.C. Wainwright Annual Global Investment
ConferenceSeptember 13 – 15,
2021Webcast: The presentation may be
accessed via webcast on demand using the following link:
https://journey.ct.events/view/ca7b4b79-1e8b-4452-b5d2-db8298a7f923
Cantor Fitzgerald Virtual Global
Healthcare ConferenceThursday, September 30, 2021
at 2:00pm ETWebcast: The presentation may
be accessed via webcast at the scheduled time, or following the
presentation, using the following link:
https://wsw.com/webcast/cantor12/cwbr/2083340
A replay of the webcasts will be available in
the events section of the CohBar website for two weeks following
the presentation.
About CohBar
CohBar (NASDAQ: CWBR) is a clinical stage
biotechnology company focused on the research and development of
mitochondria based therapeutics, an emerging class of drugs for the
treatment of chronic and age-related diseases. Mitochondria based
therapeutics originate from the discovery by CohBar’s founders of a
novel group of naturally occurring mitochondrial-derived peptides
within the mitochondrial genome that regulate metabolism and cell
death, and whose biological activity declines with age. To date,
the company has discovered more than 100 mitochondrial derived
peptides and generated over 1,000 analogs. CohBar’s efforts focus
on the development of these peptides into therapeutics that offer
the potential to address a broad range of diseases, including
nonalcoholic steatohepatitis (NASH), obesity, fibrotic diseases,
cancer, acute respiratory distress syndrome (ARDS), type 2
diabetes, and cardiovascular and neurodegenerative diseases. The
company’s lead compound, CB4211, which is under development for the
treatment of NASH and obesity, recently completed a successful
Phase 1a/1b clinical trial. In addition, CohBar has four
preclinical programs, the most advanced of which is CB5138-3, a
peptide with broad anti-fibrotic and anti-inflammatory properties.
This program is currently in IND-enabling studies with the goal of
filing an IND and initiating a First-in-Human study in 2022 with an
initial indication of idiopathic pulmonary fibrosis. The company
also has a program in ARDS, including COVID-19 associated ARDS, as
well as two peptide families with potential utility in treating
various forms of cancer.
Forward-Looking Statements
This news release contains forward-looking
statements that are not historical facts within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements are based only on our current beliefs, expectations and
assumptions regarding the future of our business, future plans and
strategies, projections, anticipated events and other future
conditions. In some cases you can identify these statements by
forward-looking words such as “believe,” “may,” “will,” “estimate,”
“continue,” “anticipate,” “intend,” “could,” “should,” “would,”
“project,” “plan,” “expect,” “goal,” “seek,” “future,” “likely” or
the negative or plural of these words or similar expressions.
Examples of such forward-looking statements include but are not
limited to statements regarding timing and anticipated outcomes of
research and clinical trials for our mitochondria based therapeutic
(MBT) candidates; expectations regarding the growth of MBTs as a
significant future class of drug products; and statements regarding
anticipated therapeutic properties and potential of our
mitochondrial peptide analogs, MBTs and other potential therapies.
You are cautioned that such statements are not guarantees of future
performance and that actual results or developments may differ
materially from those set forth in these forward-looking
statements. Factors that could cause actual results to differ
materially from these forward-looking statements include: our
ability to successfully advance drug discovery and development
programs, including the delay or termination of ongoing clinical
trials and the timing of announcements and updates relating to our
clinical trials and related data; our possible inability to
mitigate the prevalence and/or persistence of the injection site
reactions, receipt of unfavorable feedback from regulators
regarding the safety or tolerability of CB4211 or the possibility
of other developments affecting the viability of CB4211 or CB5138-3
as a clinical candidate or its commercial potential; results that
are different from earlier data results including less favorable
results that may not support further clinical development; our
ability to raise additional capital when necessary to continue our
operations; our ability to recruit and retain key management and
scientific personnel; the risk that our intellectual property may
not be adequately protected; our ability to establish and maintain
partnerships with corporate and industry partners; and risks
related to the impact on our business of the COVID-19 pandemic or
similar public health crises. Additional assumptions, risks and
uncertainties are described in detail in our registration
statements, reports and other filings with the Securities and
Exchange Commission and applicable Canadian securities regulators,
which are available on our website, and at www.sec.gov or
www.sedar.com.
You are cautioned that such statements are not
guarantees of future performance and that our actual results may
differ materially from those set forth in the forward-looking
statements. The forward-looking statements and other information
contained in this news release are made as of the date hereof and
CohBar does not undertake any obligation to update publicly or
revise any forward-looking statements or information, whether as a
result of new information, future events or otherwise, unless so
required by applicable securities laws. Nothing herein shall
constitute an offer to sell or the solicitation of an offer to buy
any securities.
Contacts: Jordyn TaraziDirector
of Investor RelationsCohBar, Inc.(650)
445-4441Jordyn.tarazi@cohbar.com
Media:Nancy ThompsonVorticom,
Inc.(212)532-2208Nancyt@vorticom.com
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Jun 2024 to Jul 2024
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Jul 2023 to Jul 2024